Biotechnology

New preclinical data reveals a novel gene therapy that not only kills tumor cells but also boosts immunity, offering hope against drug-resistant lung cancer.

A novel drug mimicking exercise aims to solve a major problem with today's weight-loss meds: muscle loss. Atrogi's ATR-258 has entered a key human trial.

DNA Script's global expansion brings benchtop DNA printers to new markets, promising to accelerate research and decentralize biotech supply chains.

The deal, part of a broader consolidation strategy by parent The Lockwood Group, aims to meet rising pharma demand for advanced data and patient services.

With late-breaking hypertension data and an AI-driven platform, Kardigan is set to showcase a new, personalized approach to cardiovascular medicine.

A new strategic partnership aims to unite California's life science hubs, creating a streamlined path to capital for medtech and biotech startups.

The FDA grants PolyPid a crucial $4.3 million fee waiver for its D-PLEX₁₀₀ drug, freeing up vital cash to accelerate its commercial launch.

Aldeyra Therapeutics' dry eye drug, reproxalap, was rejected by the FDA for a third time, citing inconsistent data and wiping out millions in value.

A new injectable dye entering Phase 3 trials promises to make lung cancer cells glow, helping surgeons remove tumors more completely and prevent recurrence.

After regaining Nasdaq compliance, Incannex Healthcare is leveraging its $75M war chest to advance novel treatments for sleep apnea and anxiety.

A new collaboration will use Voro's 'masking' technology to create tumor-activated ADCs, aiming to make powerful cancer therapies safer and more effective.

Galectin Therapeutics adds legendary neurosurgeon Dr. Henry Brem to its board, a strategic move to leverage his drug development expertise for its lead liver drug.

Exiting stealth, PerturbAI releases an 8-million-cell map of gene function in a living brain, aiming to slash the cost and time of creating new drugs.

Backed by dialysis giants DaVita and U.S. Renal Care, a new startup licenses a first-in-class therapy to transform treatment for kidney patients.

BioCardia's FDA milestone for its Helix catheter could unlock a new era of targeted heart therapies, but financial hurdles and clinical questions remain.

A new collaboration aims to predict immunotherapy success by mapping protein interactions, offering hope for personalized non-small cell lung cancer treatment.

A new telehealth model challenges the prescription-first approach, combining GLP-1s with 24/7 clinical support. Is this the future of metabolic health?

UK biotech Alchemab hires Sanofi's Ulrich Wendt as CBO to forge major pharma deals for its novel AI platform that mines the secrets of human resilience.

Pharma giant AbbVie taps biotech innovator Alloy Therapeutics to build a novel antibody platform, aiming to unlock a new generation of medicines.

The biotech reports promising clinical data for its lead alpha-therapy program and secures funding into late 2027, navigating a high-cost, high-reward path.